Biotage acquires ATDBio for $62M

By The Science Advisory Board staff writers

October 20, 2021 -- Biotage acquired the U.K.-based privately held company ATDBio for $62 million (45 million pounds).

The acquisition adds DNA and RNA oligonucleotide synthesis and purification platforms to Biotage's portfolio. The platforms are used for drug discovery, molecular diagnostics, nucleic acid-based therapeutics, and new generation DNA and RNA sequencing technologies.

This deal is expected to expand and strengthen Biotage as a leading life science tool and impact technology service provider.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.